You are here
VLP BIOTECH, INC.
UEI: JPNRGENTXC35
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
An epitope-focused nanoparticle vaccine for anthrax
Amount: $1,981,843.00Abstract We have successfully developed a highly immunogenic, optimized and lyophilizable epitope-focused, bivalent anthrax vaccine, referred to as LND-LF-VLP, using our novel proprietary platform tec ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A therapeutic vaccine for chronic hepatitis B
Amount: $1,737,018.00Project Summary/AbstractAlthough a safe and efficacious preventative vaccine for HBV has been available for 30 years, it is not effective against chronic infection. The primary cause of chronic HBV (C ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
An epitope-focused nanoparticle vaccine for anthrax
Amount: $300,000.00Abstract We have successfully developed a highly immunogenicoptimized and lyophilizable epitope focusedbivalent anthrax vaccinereferred to as LND LF VLPusing our novel proprietary platform technology ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
A method to determine mRNA isoform frequencies using novel primer generators
Amount: $225,000.00AbstractCurrent methods for RNA seq library preparation attempt to uniformly sample all sequences across every mRNA moleculeoptimally with sufficient overlap to allow de novo reassembly of the mRNA se ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
An Epitope-Focused Pediatric RSV Vaccine
Amount: $224,141.00DESCRIPTION provided by applicant Although respiratory syncytial virus RSV infection occurs in of infants during the first year of life and are infected one or more times by year repr ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
An epitope focused nanoparticle vaccine for MRSA and biodefense
Amount: $546,129.00DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
A molecularly targeted pre- and post-exposure vaccine for anthrax
Amount: $509,817.00DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies s ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
A Therapeutic Vaccine for Chronic Hepatitis B
Amount: $2,890,322.00DESCRIPTION (provided by applicant): The objective of this proposal is to assess the feasibility of using recombinant virus-like- particles (VLPs) to elicit neutralizing antibodies and prime CD4+ T c ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
A Therapeutic Vaccine for Chronic Hepatitis B
Amount: $599,513.00DESCRIPTION (provided by applicant): The objective of this proposal is to assess the feasibility of using recombinant virus-like-particles (VLPs) to elicit neutralizing antibodies and prime CD4+/CD8+ ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Development of a Proplylactic HCV Vaccine
Amount: $300,000.00DESCRIPTION (provided by applicant): The overall objective is to develop hepatitis C virus (HCV)-specific immunogens that may be useful as vaccines for the prevention of chronic HCV infection. In the ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health
